Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

LPC joins forces with One Health Group to launch first surgical hub

One Health Group is set to transform orthopaedic care in the North of England with its first surgical hub, enhancing patient access to essential NHS services...

EDX Medical Group to launch highly accurate early detection test for testicular cancer

EDX Medical Group is set to launch TC100, a groundbreaking early detection test for testicular cancer in the UK, offering unparalleled accuracy for improved patient care...

Optima Health expands into Ireland with Cognate Health acquisition

Optima Health Plc has announced its acquisition of Cognate Health Limited for up to €9 million, expanding its footprint in the Irish occupational health sector...

A powerful push for prostate cancer awareness

Bishop David Walker's prostate cancer diagnosis highlights the importance of early detection and proactive healthcare, urging men to get tested before symptoms arise...

hVIVO delivers record 2024 results, revenue up 11.9% and EBITDA up 25.9%

hVIVO plc reports impressive audited results for 2024, showcasing a revenue increase and strong EBITDA growth in the human challenge clinical trial sector...

Nuformix reports positive NXP002 results in lung disease models

Nuformix plc announces promising re-analysis results for NXP002, targeting unmet needs in fibrosis and oncology, offering insights into new treatment pathways...

Unlocking growth through untapped talent at One Health Group

Under CEO Adam Binns, One Health Group has revolutionized healthcare through innovation, talent development, and strategic growth, achieving remarkable financial success...

AstraZeneca Plc Enhertu approved in the EU for HER2 breast cancer

AstraZeneca and Daiichi Sankyo's Enhertu gains EU approval for treating HR-positive, HER2-low metastatic breast cancer, offering new hope for patients...

AstraZeneca’s Imfinzi granted FDA approval in the US for bladder cancer

AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials...

GSK Plc Nucala application for COPD accepted by EMA

GSK announces the EMA's review of Nucala (mepolizumab) as a potential add-on treatment for COPD, promising hope for 40 million patients battling this condition...

Haleon Plc publishes 2024 Annual Report

Haleon plc has released its Annual Report for 2024, detailing vital financial information and upcoming AGM plans. Discover key insights for investors now...

AstraZeneca Plc advances cell therapy ambition, acquiring EsoBiotec

AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care...

AstraZeneca Plc Imfinzi demonstrates improved EFS in early stage gastric cancer

The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer...

Hikma Pharmaceuticals Plc delivers double digit revenue growth & increased profits in FY24

Hikma Pharmaceuticals reports strong 2024 results, with double-digit revenue growth, increased profits, and strategic acquisitions fueling optimism for 2025...

Convatec Group Plc reports broad-based, sustainable and profitable growth

Convatec Group Plc reports robust FY24 results with double-digit growth in EPS and cash flow, driven by strategic execution and expanded product offerings...

GSK Plc completes acquisition of IDRx, Inc.

GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor...

GSK Plc 5-in-1 meningococcal vaccine approved by FDA

GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates...

GSK Plc reports strong growth in Specialty Medicines and R&D progress

GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns...

GSK plc Depemokimab applications accepted for review in China and Japan

GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...

GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe...
Search

Funds

Health

LPC joins forces with One Health Group to launch first surgical hub

One Health Group is set to transform orthopaedic care in the North of England with its first surgical hub, enhancing patient access to essential NHS services...

EDX Medical Group to launch highly accurate early detection test for testicular cancer

EDX Medical Group is set to launch TC100, a groundbreaking early detection test for testicular cancer in the UK, offering unparalleled accuracy for improved patient care...

Optima Health expands into Ireland with Cognate Health acquisition

Optima Health Plc has announced its acquisition of Cognate Health Limited for up to €9 million, expanding its footprint in the Irish occupational health sector...

A powerful push for prostate cancer awareness

Bishop David Walker's prostate cancer diagnosis highlights the importance of early detection and proactive healthcare, urging men to get tested before symptoms arise...

hVIVO delivers record 2024 results, revenue up 11.9% and EBITDA up 25.9%

hVIVO plc reports impressive audited results for 2024, showcasing a revenue increase and strong EBITDA growth in the human challenge clinical trial sector...

Nuformix reports positive NXP002 results in lung disease models

Nuformix plc announces promising re-analysis results for NXP002, targeting unmet needs in fibrosis and oncology, offering insights into new treatment pathways...

Unlocking growth through untapped talent at One Health Group

Under CEO Adam Binns, One Health Group has revolutionized healthcare through innovation, talent development, and strategic growth, achieving remarkable financial success...

AstraZeneca Plc Enhertu approved in the EU for HER2 breast cancer

AstraZeneca and Daiichi Sankyo's Enhertu gains EU approval for treating HR-positive, HER2-low metastatic breast cancer, offering new hope for patients...

AstraZeneca’s Imfinzi granted FDA approval in the US for bladder cancer

AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials...

GSK Plc Nucala application for COPD accepted by EMA

GSK announces the EMA's review of Nucala (mepolizumab) as a potential add-on treatment for COPD, promising hope for 40 million patients battling this condition...

Haleon Plc publishes 2024 Annual Report

Haleon plc has released its Annual Report for 2024, detailing vital financial information and upcoming AGM plans. Discover key insights for investors now...

AstraZeneca Plc advances cell therapy ambition, acquiring EsoBiotec

AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care...

AstraZeneca Plc Imfinzi demonstrates improved EFS in early stage gastric cancer

The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer...

Hikma Pharmaceuticals Plc delivers double digit revenue growth & increased profits in FY24

Hikma Pharmaceuticals reports strong 2024 results, with double-digit revenue growth, increased profits, and strategic acquisitions fueling optimism for 2025...

Convatec Group Plc reports broad-based, sustainable and profitable growth

Convatec Group Plc reports robust FY24 results with double-digit growth in EPS and cash flow, driven by strategic execution and expanded product offerings...

GSK Plc completes acquisition of IDRx, Inc.

GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor...

GSK Plc 5-in-1 meningococcal vaccine approved by FDA

GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates...

GSK Plc reports strong growth in Specialty Medicines and R&D progress

GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns...

GSK plc Depemokimab applications accepted for review in China and Japan

GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...

GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe...
Search

Funds

Health

FTSE 100

Funds